Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2023 | 1 |
2024 | 1 |
Search Results
2 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3.
Lancet. 2023.
PMID: 37931634
Clinical Trial.
Risk factors of death or chronic renal replacement therapy requirements in patients with thrombotic microangiopathies without ADAMTS-13 deficiency.
Uriol-Rivera MG, Andrade BL, Bonet AM, Mulet AO, Ruiz CB, Parraga LP, Lumbreras J, Rota JIA, Servalos MF, Balaguer JF, Ferreres LP, Valles MJP, Valero RMRG, Sanchez ST, Martin AG, Garcia JR, Cobo CG, Ramis-Cabrer D; Son Espases Multidisciplinary Team for the management of Thrombotic Microangiopathy.
Uriol-Rivera MG, et al.
Eur J Haematol. 2024 Oct;113(4):510-520. doi: 10.1111/ejh.14261. Epub 2024 Jul 2.
Eur J Haematol. 2024.
PMID: 38955806
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.